Lonza's CEO puts Merck KGaA site deal near midpoint of CHF 100-600 million range
Pharmaceutical Executive · · AI-summarised by FinFlash
Lonza chief executive Wolfgang Wienand told investors the price for five US sites from Merck KGaA sits near the midpoint of a CHF 100 million to CHF 600 million range. The sites should bring about CHF 250 million of 2028 sales at margins below Lonza's own, and add roughly 1,100 staff, taking its US sites to nine. Closing is expected in mid-2027, funded from cash and credit lines.
So What?
Barclays calls the deal strategically positive for Lonza and JPMorgan a minor positive for Merck KGaA. Lonza says it keeps its BBB+ rating, so watch margin dilution rather than leverage.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.